180 related articles for article (PubMed ID: 23132335)
21. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.
Ikeda M; Arai Y; Park SJ; Takeuchi Y; Anai H; Kim JK; Inaba Y; Aramaki T; Kwon SH; Yamamoto S; Okusaka T; ;
J Vasc Interv Radiol; 2013 Apr; 24(4):490-500. PubMed ID: 23466316
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
24. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
27. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
28. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies.
Kimura T; Aikata H; Doi Y; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Katsuta T; Kenjo M; Murakami Y; Awai K; Chayama K; Nagata Y
Technol Cancer Res Treat; 2018 Jan; 17():1533033818783450. PubMed ID: 29963972
[TBL] [Abstract][Full Text] [Related]
30. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
Kim PH; Gwon DI; Kim JW; Chu HH; Kim JH
Eur Radiol; 2020 Oct; 30(10):5650-5662. PubMed ID: 32409860
[TBL] [Abstract][Full Text] [Related]
32. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
33. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
34. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation.
Ginsburg M; Zivin SP; Wroblewski K; Doshi T; Vasnani RJ; Van Ha TG
J Vasc Interv Radiol; 2015 Mar; 26(3):330-41. PubMed ID: 25534635
[TBL] [Abstract][Full Text] [Related]
35. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
36. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Nagamatsu H; Sumie S; Niizeki T; Tajiri N; Iwamoto H; Aino H; Nakano M; Shimose S; Satani M; Okamura S; Kuromatsu R; Matsugaki S; Kurogi J; Kajiwara M; Koga H; Torimura T
Cancer Chemother Pharmacol; 2016 Feb; 77(2):243-50. PubMed ID: 26754678
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of combination therapy of chemoembolization and radiofrequency ablation with different time intervals for hepatocellular carcinoma patients.
Feng YM; Wang X; Wang L; Ma XW; Wu H; Bu HR; Xie XY; Qi JN; Zhu Q
Surg Oncol; 2017 Sep; 26(3):236-241. PubMed ID: 28807242
[TBL] [Abstract][Full Text] [Related]
38. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Ben Khaled N; Seidensticker M; Ricke J; Mayerle J; Oehrle B; Rössler D; Teupser D; Ehmer U; Bitzer M; Waldschmidt D; Fuchs M; Reuken PA; Lange CM; Wege H; Kandulski A; Dechêne A; Venerito M; Berres ML; Luedde T; Kubisch I; Reiter FP; De Toni EN
Future Oncol; 2022 Apr; 18(12):1423-1435. PubMed ID: 35081747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
